Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natalie Ball

Physician Assistant, Medical Belpre, OH Physician Assistant

NPI 1053661025 CMS profile 10729092

805 Farson St Ste 117, Belpre, OH 45714

Open in the dashboard

General payments

$8,543

507 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalie Ball of Belpre, OH is reported in the CMS Open Payments database as having received $8,543 across 507 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,793 91
2024 General $1,714 100
2023 General $1,711 105
2022 General $1,829 118
2021 General $1,495 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Ball
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Natalie Ball were reported at $1,793. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Natalie Ball Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,495 $156 $41–$563 $132
2022 $1,829 $185 $55–$649 $149
2023 $1,711 $199 $58–$717 $160
2024 $1,714 $206 $62–$740 $164
2025 $1,793 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,189 138 payments
  2. Novo Nordisk Inc $1,354 80 payments
  3. Pfizer Inc. $793 56 payments
  4. Amgen Inc. $704 43 payments
  5. AstraZeneca Pharmaceuticals LP $649 34 payments
  6. Lilly USA, LLC $510 24 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $355 21 payments
  8. GlaxoSmithKline, LLC. $289 19 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $236 15 payments
  10. Exact Sciences Corporation $146 8 payments
  11. Other $1,317 69 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,543 507 payments
Products named General payments · program years 2021–2025
  1. Ozempic $871 50 payments
  2. QULIPTA $834 46 payments
  3. UBRELVY $789 44 payments
  4. RYBELSUS $618 41 payments
  5. NURTEC ODT $490 37 payments
  6. LINZESS $462 29 payments
  7. Otezla $449 28 payments
  8. FARXIGA $427 22 payments
  9. VRAYLAR $355 31 payments
  10. Repatha $344 21 payments
  11. Other $6,381 375 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 137 drugs

Part D claims

6,132

Median for Physician Assistant: 241

Drug cost

$997,331

Median for Physician Assistant: $4,110

Branded share of claims

25.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 138 $217,962
Jardiance Empagliflozin Brand 120 $136,871
Farxiga Dapagliflozin Propanediol Brand 84 $115,260
Eliquis Apixaban Brand 117 $106,088
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $65,868
Rybelsus Semaglutide Brand 22 $45,220
Vraylar Cariprazine Hcl Brand 19 $30,561
Tresiba Flextouch U-200 Insulin Degludec Brand 24 $30,549
Mounjaro Tirzepatide Brand 19 $30,492
Linzess Linaclotide Brand 26 $27,679

The 10 drugs with the highest cost, of 137 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$32,225

Medicare's payments for the services billed

Medicare patients

232

Average age 74

Services billed

627

149 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 30%
Ischemic heart disease 26%
Atrial fibrillation 21%
Chronic kidney disease 21%
COPD 20%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $153
$153 — —
UBRELVY
  • AbbVie, Inc. $147
$147 — —
QULIPTA
  • AbbVie, Inc. $147
$147 — —
ZEPBOUND
  • Lilly USA, LLC $126
$126 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $110
$110 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

507 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record